Allarity Therapeutics(ALLR)
搜索文档
Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances
Newsfilter· 2024-05-15 04:01
- Phase 2 Trial of Stenoparib Concluded Early due to Clear Clinical Benefits Achieved - On Track to Regain Compliance with All Nasdaq Listing Requirements - No Variable Priced Securities are Outstanding - Warrant Overhang Near Elimination - Allarity Withdraws its Form S-1 - Establishes Equity of $15 Million - Cash Balance of $14 Million Boston (May 14, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing perso ...
All You Need to Know About Allarity Therapeutics, Inc. (ALLR) Rating Upgrade to Buy
Zacks Investment Research· 2024-05-08 01:01
Allarity Therapeutics, Inc. (ALLR) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Since a chan ...
Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock
Newsfilter· 2024-05-07 21:30
- Conversions Eliminate All Variable Priced Derivative Securities - Conversions Eliminate Any Market Overhang from Warrants - Series A Preferred and Warrant Conversions were Investor Initiated - Limited Number of Warrants Convertible at $20 Per Share Remain - Company Has Paid Off All Bridge Notes in Full Boston (May 7, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced ...
Allarity Therapeutics Exceeds Nasdaq's Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1
Newsfilter· 2024-05-06 20:00
- Stockholders' equity significantly surpasses the $2.5 million minimum required by Nasdaq - Company is to seek Nasdaq's formal confirmation of compliance with equity requirements under the exchange's Rule 5550(b)(1). - Company will submit a request to the SEC to withdraw Form S-1 Boston (May 6, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that its stockholders' e ...
Allarity Therapeutics' Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer
Newsfilter· 2024-05-02 20:00
Boston (May 2, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced the early discontinuation of its Phase 2 clinical trial of stenoparib, a novel PARP inhibitor, for the treatment of advanced recurrent ovarian cancer. The patients enrolled in the trial had been pre-screened by Allarity's unique Drug Response predictor (DRP®) companion diagnostic (CDx) in order to treat o ...
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement
Newsfilter· 2024-04-29 19:00
Boston (April 29, 2024) — Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that on April 27, 2024, it received formal notice from The Nasdaq Stock Market, LLC's Office of General Counsel ("Nasdaq"). This notice confirmed that the Company has regained compliance with the minimum bid price requirement as set forth in Nasdaq's Listing Rule 5550(a)(2) (the "Bid Price Rule"). Na ...
Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)
Newsfilter· 2024-04-17 21:10
公司概况 - Allarity Therapeutics, Inc.(NASDAQ:ALLR)是一家专注于开发个性化癌症治疗的临床阶段制药公司[6] 股票情况 - 公司最近实施了1比20的股票逆向拆分,旨在恢复出价合规性[4] 财务调整 - Allarity正在积极努力调整其财务结构,包括持续降低运营支出和与关键利益相关者进行谈判[4]
Why Is Allarity Therapeutics (ALLR) Stock Up 41% Today?
InvestorPlace· 2024-04-12 20:18
Allarity Therapeutics (NASDAQ:ALLR) stock is heading higher on Friday alongside heavy pre-market trading.Investors will note that this movement comes after the company announced a prospectus supplement. This alters the maximum aggregate offering price of shares sold through prospectus from $1,350,000 to $2,350,000.Allarity Therapeutics notes that it currently has 828,580 shares outstanding with a value of $7,092,593. The amendment mentions that the company has sold $1,348,908 worth of its shares and is elig ...
Allarity Therapeutics Announces 1-for-20 Reverse Stock Split
Newsfilter· 2024-04-04 21:15
Boston (April 4, 2024) — Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced the implementation of a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20 (the "Reverse Stock Split"). The Reverse Stock Split will become effective at 9:30 a.m. Eastern Time on April 9, 2024. The Company's common stock will begin trading on a split-adjusted basis wh ...
Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update
Newsfilter· 2024-03-08 20:15
Leadership Changes Led by Appointment of Co-Founder Thomas Jensen as Interim CEO and Jeremy Graff, Ph.D., former Eli Lilly Executive, as Executive AdvisorReduced Net Loss from Operations by 50% and Reduced Net Loss by 26%Announced Data in December 2023 from Advanced Ovarian Cancer Phase 2 Stenoparib Study Showing Significant Clinical Benefit Boston (March 8, 2024) — Allarity Therapeutics, Inc. ("Company") (NASDAQ:ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer tre ...